Across TCGA pan-cancer cohorts, IGHD2-21 RNA is linked to patient survival in 15 of 34 cancer types, making it the most broadly survival-associated IGHD2-21 data layer.
The strongest signal is observed in thyroid carcinoma (THCA), where higher IGHD2-21 RNA is associated with worse overall survival. In most high-consensus cancer types, elevated IGHD2-21 expression acts as an unfavorable survival marker, although some lineages such as HNSC and MESO show a favorable association.
THCA, KIRC, and ACC are the cancer types where IGHD2-21 RNA most reproducibly stratifies survival.
RNA survival associations by lineage
Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.